SEARCH

SEARCH BY CITATION

References

  • 1
    Poynard T , Yuen MF , Ratziu V , Lai CL . Viral hepatitis C . Lancet 2003 ; 362 : 20952100 .
  • 2
    Chen CH , Yu ML . Evolution of interferon-based therapy for chronic hepatitis C . Hepat Res Treat 2010 ; 2010 : 140953 .
  • 3
    Lange CM , Zeuzem S . IL28B single nucleotide polymorphisms in the treatment of hepatitis C . J Hepatol 2011 ; 55 : 692701 .
  • 4
    Moraes Coelho HS , Villela-Nogueira CA . Predictors of response to chronic hepatitis C treatment . Ann Hepatol 2010 ; 9 : 5460 .
  • 5
    Giannelli G , Guadagnino G , Dentico P , Antonelli G , Antonaci S . MxA and PKR expression in chronic hepatitis C . J Interferon Cytokine Res 2004 ; 24 : 659663 .
  • 6
    Asahina Y , Izumi N , Umeda N et al. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon-α-2b and ribavirin . J Viral Hepat 2007 ; 14 : 396403 .
  • 7
    van der Eijk AA , Vrolijk JM , Haagmans BL . Antibodies neutralizing peginterferon α during retreatment of hepatitis C . N Engl J Med 2006 ; 354 : 13231324 .
  • 8
    Santantonio T , Milella M , Antonelli G , Scagnolari C . Neutralizing antibodies to interferon-α in a chronic hepatitis C patient non-responder to pegylated interferon . J Hepatol 2006 ; 45 : 759761 .
  • 9
    Halfon P , Pérusat S , Bourlière M et al. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy) . J Med Virol 2010 ; 82 : 20272031 .
  • 10
    Antonelli G . Biological basis for a proper clinical application of α interferons . New Microbiol 2008 ; 31 : 305318 .
  • 11
    Scagnolari C , Casato M , Bellomi F et al. Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia . Clin Diagn Lab Immunol 2003 ; 10 : 7077 .
  • 12
    Bagnato F , Clemenzi A , Scagnolari C et al. Neutralizing antibodies against endogenous interferon in myasthenia gravis patients . Eur Cytokine Netw 2004 ; 15 : 2429 .
  • 13
    Kawade Y . Quantitation of neutralization of interferon by antibody . Methods Enzymol 1986 ; 119 : 558573 .
  • 14
    Grossberg SE , Kawade Y . The expression of potency of neutralizing antibodies for interferons and other cytokines . Biotherapy 1997 ; 10 : 9398 .
  • 15
    Grossberg SE , Kawade Y , Kohase M , Klein JP . The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit . J Interferon Cytokine Res 2001 ; 21 : 743755 .
  • 16
    Harris JM , Chess RB . Effect of pegylation on pharmaceuticals . Nat Rev Drug Discov 2003 ; 2 : 214221 .
  • 17
    Singh SK . Impact of product-related factors on immunogenicity of biotherapeutics . J Pharm Sci 2011 ; 100 : 354387 .
  • 18
    Antonelli G . In vivo development of antibody to interferons: an update to 1996 . J Interferon Cytokine Res 1997 ; 17 : S39S46 .
  • 19
    Rönnblom LE , Janson ET , Perers A , Oberg KE , Alm GV . Characterization of anti-interferon-α antibodies appearing during recombinant interferon-α 2a treatment . Clin Exp Immunol 1992 ; 89 : 330335 .
  • 20
    Prümmer O . Interferon-α antibodies in patients with renal cell carcinoma treated with recombinant interferon-α-2A in an adjuvant multicenter trial. The Delta-P Study Group . Cancer 1993 ; 71 : 18281834 .
  • 21
    Brand CM , Leadbeater L , Bellati G , Marotta F , Ideo G . Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-α subtypes . J Interferon Res 1993 ; 13 : 121125 .
  • 22
    Jorns C , Holzinger D , Thimme R et al. Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis C non-responsive to IFN-α . J Med Virol 2006 ; 78 : 7482 .
  • 23
    Nolte KU , Günther G , von Wussow P . Epitopes recognized by neutralizing therapy-induced human anti-interferon-α antibodies are localized within the N-terminal functional domain of recombinant interferon-α 2 . Eur J Immunol 1996 ; 26 : 21552159 .
  • 24
    Milella M , Antonelli G , Santantonio T et al. Neutralizing antibodies to recombinant-α-interferon and response to therapy in chronic hepatitis C virus infection . Liver 1993 ; 13 : 146150 .
  • 25
    Leroy V , Baud M , de Traversay C , Maynard-Muet M , Lebon P , Zarski JP . Role of anti-interferon antibodies in breakthrough occurrence during-α 2a and 2b therapy in patients with chronic hepatitis C . J Hepatol 1998 ; 28 : 375381 .
  • 26
    Bonetti P , Diodati G , Drago C et al. Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon-α 2a . J Hepatol 1994 ; 20 : 416420 .
  • 27
    Goodin DS , Frohman EM , Hurwitz B et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology . Neurology 2007 ; 68 : 977984 .
  • 28
    Milella M , Antonelli G , Santantonio T et al. Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN . Hepatogastroenterology 1995 ; 42 : 201204 .
  • 29
    Berg T , Hopf U , Schuff-Werner P . Sustained remission of chronic hepatitis C after a change to human leukocyte interferon-α in a difficult-to-treat patient with breakthrough phenomenon associated with antibodies against recombinant interferon-α . Am J Gastroenterol 2001 ; 96 : 612614 .
    Direct Link: